EUVIMEDEUVIMED entdecken
Crossref

HBcrAg is associated with prognosis of hepatitis B virus‐related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy

Jian Liu iD, Xiaofeng Zhang, Jianbo Lin, Chun Dai, Zhihao Xie, Xintong Shi, Bin Zhu, Longjiu Cui, Yeye Wu, Yuanming Jing, Xiaohui Fu, Wenlong Yu und 2 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Jian Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Hepatitis B Core Antigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the Program of Shanghai Academic/Technology Research Leader, Shanghai Military Civil Integration Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serum hepatitis B core‐related antigen (HBcrAg) is considered a surrogate marker of the amount and activity of intrahepatic covalently closed circular DNA. This study aimed to explore the prognostic value of HBcrAg on patients with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after curative hepatectomy undergoing antiviral therapy (AVT). Data of 949 consecutive patients with HBV‐related HCC undergoing curative resection between 2010 and 2013 were reviewed. Serum HBcrAg levels were measured at surgery (baseline) for all patients and at the time of 2 years postoperatively (on‐treatment) for those without recurrence. Primary endpoint was tumor recurrence. High HBcrAg levels are associated with malignant phenotypes. HBcrAg independently affected both recurrence and overall survival (OS) in patients with negative hepatitis B e antigen (HBeAg−, p = .007 and p = .042, respectively) but not in their positive HBeAg (HBeAg+) counterparts ( p = .100 and p = .075, respectively). Patients with high baseline HBcrAg had higher late, but not early recurrence rates than those with low baseline HBcrAg levels, regardless of HBeAg status (HBeAg+: p = .307 for early, p = .001 for late; HBeAg−: p = .937 for early, p < .001 for late). On‐treatment HBcrAg independently affected late recurrence in patients stratified by both cirrhosis and HBeAg ( p < .001 for all). The predictive power of HBcrAg kinetics for late recurrence was better than that of the baseline and on‐treatment HBcrAg. High HBcrAg levels during long‐term AVT are associated with late recurrence of HCC after hepatectomy. Combining baseline and on‐treatment HBcrAg might be valuable in identifying patients at a high risk of relapse and stratifying surveillance strategies postoperatively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntiviral AgentsHepatitis B Core AntigensHepatitis BHumansMaleFemaleHepatectomyMiddle AgedPrognosisHepatitis B virusNeoplasm Recurrence, LocalAgedAdultHepatitis B e AntigensBiomarkers, Tumor

Stichwörter der Autor:innen

antiviral therapyhepatitis B core‐related antigenhepatocellular carcinomaoverall survivalrecurrence

Substanzen

Antiviral AgentsHepatitis B Core AntigensHepatitis B e AntigensBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hepatic Surgery, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
  • Department of Biliary Surgery, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Tenth People's Hospital of Tongji University, Shanghai, China.
  • Department of Gastroenterological Surgery, People's Hospital of Yang Zhong, Zhenjiang, Jiangsu Province, China.
  • Department of Gastrointestinal Surgery, People's Hospital of Shaoxing, Shaoxing, Zhejiang Province, China.

ORCID-Profile: Jian Liu

Förderung

  • the Program of Shanghai Academic/Technology Research Leader
  • Shanghai Military Civil Integration Project
  • National Natural Science Foundation of China

Zitieren

APA

Liu, J., Zhang, X., Lin, J., Dai, C., Xie, Z., Shi, X., Zhu, B., Cui, L., Wu, Y., Jing, Y., Fu, X., Yu, W., Wang, K., & Li, J. (2025). HBcrAg is associated with prognosis of hepatitis B virus‐related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.35224

Vancouver

Liu J, Zhang X, Lin J, Dai C, Xie Z, Shi X, et al. HBcrAg is associated with prognosis of hepatitis B virus‐related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy. International Journal of Cancer. 2025. doi:10.1002/ijc.35224

BibTeX
@article{Liu2025,
  author = {Liu, Jian and Zhang, Xiaofeng and Lin, Jianbo and Dai, Chun and Xie, Zhihao and Shi, Xintong and Zhu, Bin and Cui, Longjiu and Wu, Yeye and Jing, Yuanming and Fu, Xiaohui and Yu, Wenlong and Wang, Kui and Li, Jun},
  title = {HBcrAg is associated with prognosis of hepatitis B virus‐related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35224}
}
Kostenlos starten →